With reference to the subject cited, this is to inform the Exchange that the Board of Directors of Oxygenta Pharmaceutical Limited, at its Meeting held on Wednesday, 04th February, 2026, ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board of Oxygenta Pharmaceutical Ltd met on February 4, 2026 and approved unaudited financial results for Q3 and nine months ended December 31, 2025, along with the limited review report. Revenue for Q3 was Rs 339.09 lakhs, up only marginally from Rs 332.06 lakhs in the same quarter last year. However, the company reported a steepening net loss of Rs 843.30 lakhs for the quarter, much wider than the Rs 493.04 lakhs loss a year ago, with loss per share of Rs 1.32. For the nine months, the net loss stood at Rs 1,191.02 lakhs versus Rs 1,145.50 lakhs in the prior period. The board also reconstituted its Internal Complaints Committee under the POSH Act. Statutory auditors A.M. Reddy & D.R. Reddy issued a clean limited review report with no qualifications.
Despite a small revenue uptick, the widening quarterly loss and persistent negative earnings signal continued operational stress for shareholders. The stock may see negative sentiment given deteriorating profitability, though the auditor's clean review report avoids an immediate compliance concern.